Iodine-131 Anti-B1 Antibody

DRUG7 trials

Sponsors

Corixa Corporation, GlaxoSmithKline

Conditions

Chronic Lymphocytic LeukemiaLymphoma, Non-HodgkinMantle Cell LymphomaNon-Hodgkin's Lymphoma

Phase 1

Safety and Efficacy of Iodine-131 Anti-B1 Antibody for NHL Patients With Greater Than 25% Bone Marrow Involvement

Corixa CorporationNon-Hodgkin's Lymphoma

Start: 1999-05-31Target: 24Updated: 2005-06-24

Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for Chronic Lymphocytic Leukemia

Corixa CorporationChronic Lymphocytic Leukemia

Start: 1999-07-31Target: 30Updated: 2005-06-24

Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Non Hodgkin's Lymphoma (NHL) Patients With Greater Than 25% Bone Marrow Involvement

CompletedNCT00992758

GlaxoSmithKlineLymphoma, Non-Hodgkin

Start: 1999-05-28End: 2012-06-07Updated: 2017-07-25

Phase 2

Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma

CompletedNCT00022945

Corixa CorporationMantle Cell Lymphoma

Updated: 2005-06-24

Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Intermediate Grade Non-Hodgkin's Lymphoma Following First Line CHOP

Corixa CorporationNon-Hodgkin's Lymphoma

Start: 2000-01-31Updated: 2005-06-24

Unknown Phase

Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for the Retreatment of Patients With Non-Hodgkin's Lymphoma

Corixa CorporationNon-Hodgkin's Lymphoma

Updated: 2005-06-24

Expanded Access Study of Iodine-131 Anti-B1 Antibody

Corixa CorporationNon-Hodgkin's Lymphoma

Start: 1998-09-30Updated: 2005-06-24

Related Papers

Phase 2 Study of Iodine-131 Tositumomab Plus Chemotherapy in Patients With Previously Untreated Mantle-Cell Lymphoma.

2019-04-292 citations